Epigenomics Signs Joint Commercialisation Agreement for Epi proColon in North America with Polymedco

Epigenomics AG, the German–American cancer molecular diagnostics company, has entered into a joint commercialisation agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialise Epi proColon, Epigenomics' blood-based test for colorectal cancer (CRC) screening, in North America.

Under the terms of the agreement, Polymedco will deploy its CRC dedicated sales force and technical support staff, administration, logistics and other support functions to ensure the optimum market introduction and roll-out of Epi proColon once the test is potentially approved by FDA. Both parties will work jointly on the marketing, launch and development strategies and with key payers to obtain favorable reimbursement coverage.

Epigenomics will retain the responsibility to manufacture the product and to support it from the medical and regulatory point of view, including activities necessary to achieve inclusion in major cancer screening guidelines post approval. A working group comprising representatives of both companies will oversee the launch and commercial roll-out and engage in activities necessary to ensure the commercial success of the product once it becomes available to the market. The companies agreed to a combined transfer price and profit sharing agreement subject to minimum annual sales of test kits from Epigenomics to Polymedco.